Weiwei Fu
Impact in
-
- Acupuncture Treatment Research Studies
-
- Sirtuins and Resveratrol in Medicine
Papers in
-
- Ubiquitin and proteasome pathways 1
-
- Prostate Cancer Treatment and Research 2
- Renal cell carcinoma treatment 1
- Co-authors
- Tong Wang (1 shared paper)Jianchun Yu (1 shared paper)Cun‐Zhi Liu (1 shared paper)Jingxian Han (1 shared paper)Xuezhu Zhang (1 shared paper)Mei Qi (3 shared papers)Bo Han (3 shared papers)Lin Wang (2 shared papers)
In The Last Decade
Weiwei Fu
19 papers receiving 373 citations
Peers
Comparison fields: 5 of 58
- Complementary and alternative medicine 58
- Geriatrics and Gerontology 17
- Cancer Research 71
- Immunology 48
- Neurology 18
Countries citing papers authored by Weiwei Fu
This map shows the geographic impact of Weiwei Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Fu more than expected).
Fields of papers citing papers by Weiwei Fu
This network shows the impact of papers produced by Weiwei Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Fu. The network helps show where Weiwei Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Weiwei Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 79 | |
| 2 | 2015 | 54 | |
| 3 | 2014 | 53 | |
| 4 | 2018 | 49 | |
| 5 | 2020 | 45 | |
| 6 | 2014 | 27 | |
| 7 | 2019 | 16 | |
| 8 | Thyroid-like Follicular Carcinoma of the Kidney and Papillary Renal Cell Carcinoma with Thyroid-like Feature: Comparison of Two Cases and Literature Review. | 2015 | 9 |
| 9 | 2021 | 8 | |
| 10 | 2018 | 8 | |
| 11 | 2021 | 6 | |
| 12 | Primary meningeal melanocytoma located in foramen magnum: a case report and review of the literatures. | 2012 | 6 |
| 13 | 2022 | 5 | |
| 14 | 2024 | 5 | |
| 15 | 2020 | 5 | |
| 16 | 2025 | 1 | |
| 17 | 2020 | 1 | |
| 18 | 2021 | 1 | |
| 19 | 2017 | 1 | |
| 20 | 2025 | 0 |
About Weiwei Fu
Weiwei Fu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Genetics, Epidemiology and Surgery, having authored 20 papers that have together received 379 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (2 papers), Hippo pathway signaling and YAP/TAZ (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Alzheimer's disease research and treatments (1 paper), Ubiquitin and proteasome pathways (1 paper), Renal cell carcinoma treatment (1 paper) and Galectins and Cancer Biology (1 paper). The work is most often cited by research in Complementary and alternative medicine (58 citations), Geriatrics and Gerontology (17 citations), Cancer Research (71 citations), Immunology (48 citations) and Neurology (18 citations). Weiwei Fu has collaborated with scholars based in China, Estonia and Maldives. Frequent co-authors include Tong Wang, Jianchun Yu, Cun‐Zhi Liu, Jingxian Han, Xuezhu Zhang, Mei Qi, Bo Han, Lin Wang, Chunni Wang and Yujun Li. Their work appears in journals such as Disease Markers, The Prostate, Advanced Science, BioMed Research International and Molecular Carcinogenesis.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.